Risk of Fatal and Non-fatal Coronary Heart Disease and Stroke Events among Adult Patients with hypertension: Basic Markov Model Inputs for Evaluating Cost-effectiveness of Hypertension Treatment: Systematic review of Coh

10^th World Congress on Hypertension, Cardiology, Primary Health and Patient Care

October 25-26, 2022 | Webinar

Mende Mensa Sorato

PhD in Pharmacoeconomics and pharmaceutical administration at Arba Minch University, Ethiopia

Scientific Tracks Abstracts: J Hypertens (Los Angel)

Abstract :

Markov model like cardiovascular disease (CVD) policy model based simulation is being for evaluating cost- effectiveness of hypertension treatment. Stroke, angina, myocardial infarction (MI), cardiac arrest and all-cause mortality were included in this model. Hypertension risk factor for a number of vascular and cardiac complications as CVD outcomes. Therefore, this systematic review was conducted to evaluate the comprehensiveness of this model across different regions. We searched articles written in English language from PubMed/Medline, Ovid/Medline, Embase, Scopus, Web of Science and Google scholar with systematic search query. Results: Thirteen cohort studies involving total 2,165,770 (1,666,554 hypertensive adult population and 499,226 adults with treatment resistant hypertension) were included in this scoping review. Hypertension is clearly associated with coronary heart disease (CHD) and stroke mortality, unstable angina, stable angina, MI, heart failure (HF), sudden cardiac death, transient ischemic attack, ischemic stroke, sub-arachnoid hemorrhage, intracranial hemorrhage, peripheral arterial disease (PAD), and abdominal aortic aneurism (AAA). Association between HF and hypertension is variable across regions. Treatment resistant hypertension is associated with higher relative risk of developing major cardiovascular events and all-cause mortality when compared with the non-resistant hypertension. However, it is not included in the previous CVD policy model.Conclusion: The CVD policy model used can be used in most of the regions for evaluation of cost-effectiveness of hypertension treatment. However, hypertension is highly associated with HF in Latin America, the Caribbean, Eastern Europe, and Sub-Saharan Africa. Therefore, it is important to consider HF in CVD policy model for evaluating cost-effectiveness of hypertension treatment in these regions. We do not suggest the inclusion of PAD and AAA in CVD policy model for evaluating cost-effectiveness of hypertension treatment due to lack of sufficient evidence. Researchers should consider the effect of treatment resistant hypertension either through including in the basic model or during setting the model assumptions.

Biography :

Mr.Mende Mende Sorato has completed his B Pharm, M.sc and PhD in Pharmacoeconomics and Pharmaceutical administration at Arba Minch University, College of Medicine and health sciences in Ethiopia.